Humacyte (HUMA) amends revenue interest purchase agreement; $50M repayment, discounted call option

Humacyte, Inc.

Company to make $50.0M repayment under Purchase Agreement from restricted cash.
Obligation to maintain $50.0M restricted cash removed; if not repaid by Dec 31, 2025, $12.5M required.
Call option at discounted repurchase price of $95.5M if exercised on or before Dec 31, 2025; up to $7.5M may be paid in stock.
Amendment executed with TPC Investments III LP and TPC Investment Solutions LP, agented by Hook SA LLC.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.